Good Laboratory Practice

The Organization for Economic Cooperation and Development (OECD) Principles of Good Laboratory Practice (GLP) are a quality framework concerned with organizational processes. These principles define the circumstances under which non-clinical health and environmental safety studies are planned, performed, monitored, recorded, reported, and archived.

Non-clinical health and environmental safety studies covered by GLP standards include work conducted in laboratories, greenhouses, and in the field.

GLP standards are applied to non-clinical safety testing of test items contained in pharmaceuticals, pesticides, cosmetics, veterinary drugs, as well as food additives, feed additives, and modern synthetic substances.

SDAB (GLP) accreditation is granted by the relevant authority and requires laboratories to comply with the latest OECD standards for Good Laboratory Practice.

A Comprehensive Guide to Quality, Integrity, and Reliability in Non-Clinical Safety Studies

Introduction: The Imperative for Trust in Science

In a world increasingly reliant on chemical and biological products—from life-saving pharmaceuticals and safe food supplies to innovative industrial materials and crop-protecting pesticides—the question of safety is paramount. How do regulatory authorities, and by extension the public, trust that a new drug will not cause unforeseen harm, or that a novel pesticide will not devastate ecosystems? This trust is built upon a foundation of rigorous, reliable, and transparent safety data. This is the domain of Good Laboratory Practice (GLP).

GLP is not a set of scientific methods or a measure of technical competence in conducting a specific test. It is a holistic quality system governing the organizational processes and conditions under which non-clinical health and environmental safety studies are planned, performed, monitored, recorded, archived, and reported. It is a framework for management accountability, ensuring that every piece of data generated is traceable, verifiable, and an accurate reflection of the study’s conduct.

This comprehensive guide delves into the origins, core principles, operational components, and global impact of GLP, with a specific focus on the OECD Principles as the international gold standard.

Part 1: Historical Context and Evolution of GLP

1.1 The Catalyzing Crisis: Why GLP Was Born

The formal concept of GLP emerged in the 1970s in the United States, not from proactive planning, but in response to significant failures in the regulatory system. Investigations by the U.S. Food and Drug Administration (FDA) uncovered egregious instances of fraud, negligence, and poor practice in toxicology laboratories contracted to perform safety studies for new drugs.

Key findings included:

Fabrication of Data: Inventing results for tests that were never performed.
Selective Reporting: Omitting unfavorable data that indicated toxicity.
Poor Animal Care: Inadequate husbandry leading to compromised study outcomes.
Inadequate Personnel Training: Technicians lacking the skills to perform complex studies.
Insufficient Documentation: Inability to reconstruct studies from raw data.

The most infamous case involved the testing facility Industrial Bio-Test Laboratories. The subsequent scandal revealed that data for numerous pesticides, drugs, and other chemicals was invalid, forcing regulators to re-evaluate hundreds of products already on the market. This crisis fundamentally eroded trust in the entire safety assessment process.

1.2 The Regulatory Response: The Birth of Formal GLP

In reaction, the FDA promulgated the first formal GLP regulations in 1978 (21 CFR Part 58). These rules established mandatory requirements for the conduct of non-clinical laboratory studies. The core philosophy was clear: to ensure the quality and integrity of safety data submitted to regulatory authorities.

1.3 The OECD and International Harmonization

As other industrialized nations developed their own GLP frameworks, a critical problem emerged: divergence. A study conducted in Japan under Japanese GLP rules might not be fully accepted by regulators in Germany or the United States. This created duplicative testing, increased costs for industry, and delayed the availability of important products while creating unnecessary animal testing.

To address this, the Organization for Economic Co-operation and Development (OECD) took a leading role. In 1981, the OECD Council established the “Decision of the Council concerning the Mutual Acceptance of Data (MAD) in the Assessment of Chemicals” (C(81)30(Final)). This landmark decision stipulated that safety data generated in an OECD member country in accordance with OECD Test Guidelines and OECD Principles of GLP must be accepted by other OECD members for regulatory purposes.

The first OECD GLP Principles were published in 1981 and have been regularly revised (1997, 1998) to keep pace with scientific and technical developments. The MAD system, underpinned by harmonized GLP Principles, is a cornerstone of international regulatory cooperation, facilitating trade, promoting efficiency, and upholding high standards of safety and environmental protection.

1.4 Scope and Application: What Does GLP Cover?

As outlined in the introduction, GLP applies specifically to non-clinical health and environmental safety studies. These are studies intended to determine the potential hazards of a test item—its toxicity, pharmacokinetics, environmental fate, ecotoxicity—prior to clinical trials in humans or release into the environment.

Key Inclusions:

Test Items: Pharmaceuticals, pesticides, cosmetics, veterinary drugs, food and feed additives, industrial chemicals, novel synthetic materials, and genetically modified organisms.
Test Systems: Animals (in vivo), plants, microorganisms, and sub-cellular systems (in vitro).
Study Locations: Traditional laboratories, animal facilities, greenhouses, and field sites (e.g., for environmental fate studies of pesticides).

Key Exclusions:

Basic Research: Exploratory scientific research not intended for regulatory submission.
Clinical Trials: Studies involving human subjects (governed by Good Clinical Practice, GCP).
Routine Quality Control: Analytical testing for batch release of marketed products (governed by Good Manufacturing Practice, GMP).
Chemical Analysis for Non-Regulatory Purposes: Though many analytical labs adopt GLP-like quality systems.

Part 2: The OECD Principles of GLP – A Detailed Examination

The OECD Principles of GLP are structured around ten core areas that collectively define the quality system. Each principle assigns clear responsibilities to key personnel within a test facility.

2.1 Principle 1: Test Facility Organization and Personnel

This principle establishes the fundamental requirement for a clear organizational structure with defined lines of authority and responsibility.

Management Responsibilities:
- Appoint a Study Director for each study.
- Appoint a Quality Assurance Unit (QAU).
- Ensure sufficient qualified personnel, resources, and facilities.
- Ensure test and control articles are appropriately characterized.
- Establish and implement Standard Operating Procedures (SOPs).
- Ensure QAU responsibilities are performed and documented.
Study Director Responsibilities: The single point of control for the entire study. The Study Director has ultimate responsibility for the technical conduct, interpretation, analysis, documentation, and reporting of the study. He/she must approve the study plan and any amendments, ensure compliance with GLP, and sign the final report to certify its accuracy.
Quality Assurance Unit (QAU) Responsibilities: An independent entity within the test facility. The QAU is responsible for monitoring the study to assure management that facilities, equipment, personnel, methods, practices, records, and controls conform to GLP Principles. It does this through facility-based and study-based inspections and audits of final reports. The QAU must report its findings in writing to management and the Study Director.
Personnel Responsibilities: All individuals must have the education, training, and experience necessary to perform their roles. They must have access to the study plan and SOPs, exercise health precautions to avoid contamination, and wear appropriate attire.

2.2 Principle 2: Quality Assurance Programme

This principle details the function of the QAU. Its role is assurance, not direct responsibility for study quality (which remains with the Study Director and management). Key activities include:

Maintaining a master schedule of all studies.
Reviewing study plans for GLP compliance.
Conducting facility inspections (of processes like animal care, test article handling).
Conducting process-based inspections (of ongoing study activities like dosing, clinical observations).
Conducting data and report audits (verifying that raw data accurately supports the final report findings).
Reporting inspection/audit findings.
Maintaining QAU records and documentation.

2.3 Principle 3: Facilities

GLP requires facilities that are of suitable size, construction, and location to enable the proper conduct of studies and minimize disturbances.

Test System Facilities: Designed to ensure proper separation of species, studies, and test systems (e.g., quarantine areas, diagnostic labs).
Test Article Facilities: Separate areas for receipt, storage, handling (mixing), and characterization of test and control articles to prevent mix-up, contamination, or degradation.
Archive Facilities: Secure, dedicated space for the storage and retrieval of raw data, reports, specimens, and samples.
Waste Disposal: Appropriate facilities for the collection, storage, and disposal of waste to avoid interference with the study.

2.4 Principle 4: Apparatus, Material, and Reagents

Apparatus (equipment) used for data generation, environmental control, and measurement must be suitably located, of appropriate design and capacity, and adequately maintained.
A program of preventive maintenance, calibration, and performance verification must be established and documented.
SOPs must exist for the operation, maintenance, and calibration of critical equipment.
Chemicals, reagents, and solutions must be labeled with identity, concentration, expiry date, and storage instructions.

2.5 Principle 5: Test Systems

Physical/chemical or biological systems used in a study must be appropriately characterized, sourced, and maintained.

Biological Test Systems: Records must document source, date of arrival, condition upon arrival, and acclimatization period. Proper identification of individual animals or plants is crucial. Diagnosis and treatment of disease must be documented.
Physical/Chemical Test Systems: Must be validated and characterized (e.g., a validated analytical method or a soil type used in an ecotoxicology study).

2.6 Principle 6: Test and Reference Items

This principle ensures the unambiguous identification, proper handling, and known composition of the substances being tested.

Characterization: Each batch of test and reference item must be appropriately characterized. This includes documentation of identity, batch number, purity, composition, concentration, stability, and other properties relevant to the study.
Handling: Procedures must prevent contamination, mix-up, or deterioration. Storage containers must be labeled and storage conditions documented.
Formulation for Administration: For studies where the item is mixed with a vehicle, the homogeneity, concentration, and stability of the formulation must be determined.

2.7 Principle 7: Standard Operating Procedures (SOPs)

SOPs are the written, detailed instructions that ensure the consistency and quality of routine operations. They are the backbone of the GLP quality system.

Purpose: To achieve uniformity in the performance of a specific function across time and personnel.
Content: SOPs must be approved by management, be readily available at the relevant workstations, and be written in a clear, instructional style.
Scope: SOPs should exist for a vast range of activities: test system receipt and care, apparatus maintenance, test article handling, sample collection, data processing, reporting, QAU functions, etc.
Deviations: Any deviation from an SOP must be authorized by the Study Director and documented.

2.8 Principle 8: Performance of the Study

This principle governs the entire lifecycle of a study, from inception to completion.

The Study Plan (Protocol): The master document defining the study’s objectives and methods. It must be approved by the Study Director and contain specific elements: identification of test item, sponsor, test facility; experimental design; detailed procedures; records to be maintained; and the date of approval.
Study Plan Amendments: Any change to the study plan after initiation must be justified, documented as a formal amendment, and signed/dated by the Study Director.
Conduct of the Study: A unique identification must be given to the study. All data generated must be recorded directly, promptly, accurately, and legibly by the person performing the work. Any changes to data must be made in a way that does not obscure the original entry, must be dated, and must include a reason for the change.

2.9 Principle 9: Reporting of Study Results

The final report is the ultimate output and must provide a complete, accurate account of the study.

Content: The report must include all information specified in the OECD Principles, such as a statement of GLP compliance, details of test item and test system, statistical methods, results (including all raw data), a discussion, and conclusions.
Responsibility: The Study Director must sign and date the final report, providing a declaration of GLP compliance and assuming responsibility for the validity of the data.
QAU Statement: The final report must contain a signed and dated statement from the QAU detailing the types of inspections and dates they were performed, and confirming that the final report accurately reflects the raw data.
Report Amendments: Corrections or additions to a finalized report must be made in the form of an amendment, clearly stating the reason and appended to the original report.

2.10 Principle 10: Storage and Retention of Records and Materials

The ability to reconstruct a study years later is a cornerstone of GLP. This requires the secure archiving of all records and specimens.

The Archive: Must be a designated facility with controlled access, managed by an archivist. It must protect contents from fire, water damage, pests, and deterioration.
Retention Period: Archives must be retained for a period specified by the appropriate regulatory authorities (often at least 15 years after study completion or the last regulatory submission, or longer).
Material to be Archived: Includes the study plan, raw data, final report, specimens, and correspondence. The QAU’s records and SOPs must also be archived.
Retrieval: Systems must be in place for the authorized retrieval of archived materials.

Part 3: GLP in Practice: The Lifecycle of a Study

To understand how the principles interconnect, it is useful to follow a typical study’s path.

Phase 1: Initiation & Planning
A Sponsor (e.g., a pharmaceutical company) commissions a study at a GLP-compliant Test Facility. Management appoints a Study Director. The Study Director drafts the Study Plan in consultation with experts. The QAU reviews the plan for GLP compliance. The Sponsor and Study Director approve the plan.

Phase 2: Study Set-Up
The characterized test article is received and logged. Test systems (e.g., laboratory animals) are ordered, received, and acclimatized. Technicians are trained on relevant SOPs. Equipment is verified as calibrated and operational.

Phase 3: In-Life Conduct
The study procedures commence (dosing, observations, sample collection). The Study Director supervises all activities. Technicians record all raw data contemporaneously. The QAU conducts process-based inspections. Any deviations are documented and assessed by the Study Director. Stability of the test article formulation is checked.

Phase 4: Analysis & Reporting
Collected samples (e.g., blood, tissue) are analyzed. Analytical data is processed. The Study Director reviews all data, interprets results, and drafts the Final Report. Statisticians may analyze the data. The QAU performs a data and report audit, comparing the final report against the raw data archives.

Phase 5: Archival
Upon QAU certification and Study Director sign-off, the finalized report is issued to the Sponsor. The Study Director then ensures all study materials—the approved plan, raw data, specimens, and final report—are transferred to the archive for secure, long-term retention.

Part 4: Accreditation, Compliance Monitoring, and Global Impact

4.1 National Compliance Monitoring Authorities

OECD member countries designate a National GLP Compliance Monitoring Authority (often within a ministry of health, environment, or agriculture). For example:

USA: FDA (for pharmaceuticals, food) and EPA (for pesticides, chemicals).
UK: UK GLP Monitoring Authority (UK GLPMA).
Japan: Ministry of Health, Labour and Welfare (MHLW) and others.
Germany: Federal Institute for Drugs and Medical Devices (BfArM).

These authorities are responsible for:

Inspecting test facilities to assess compliance with GLP Principles.
Issuing compliance statements for facilities that pass inspection.
Maintaining a list of GLP-compliant facilities.
Participating in OECD working groups to ensure international harmonization.

As mentioned, SDAB (GLP) accreditation refers to the specific accreditation granted by a national authority (the “relevant authority”) following a successful assessment against the latest OECD standards. The term “SDAB” may be a specific national program acronym.

4.2 The Mutual Acceptance of Data (MAD) System

The power of OECD GLP lies in the MAD system. If a study is conducted in an OECD member country (or a full adherent to the MAD system like South Africa or Singapore) in compliance with OECD GLP, regulatory authorities in all other member countries are obligated to accept that data for assessment. This:

Eliminates duplicative testing, saving time, money, and animals.
Reduces non-tariff barriers to trade.
Promotes consistent global safety standards.
Encourages international collaboration and trust among regulators.

4.3 Challenges and Future Directions

New Modalities: Adapting GLP principles to novel test items like advanced therapy medicinal products (cell and gene therapies) and nanomaterials.
New Approach Methodologies (NAMs): Incorporating non-animal methods (in vitro, in silico) within the GLP framework requires flexibility while maintaining data integrity.
Digital Transformation: Managing electronic data (e.g., from complex imaging systems, digital pathology) with GLP-required controls for data integrity (ALCOA+: Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available).
Global Expansion: Extending the MAD system to more non-OECD economies while maintaining rigorous oversight.

Conclusion

Good Laboratory Practice is far more than a regulatory checklist. It is an ethical and scientific imperative. By mandating rigorous management control, transparent documentation, independent verification, and long-term data preservation, GLP creates an environment where scientific integrity is structurally enforced. It ensures that the data upon which critical decisions about human health and environmental protection are based is trustworthy.

From its origins in scandal to its current status as a globally harmonized system underpinning international trade and safety, GLP represents a profound commitment to quality in science. It protects not only the end consumer and the environment but also the reputation of the scientific enterprise itself. In a world of increasingly complex technological and chemical challenges, the principles of GLP—accountability, traceability, and transparency—remain more vital than ever. They are the silent guardians of safety, ensuring that progress does not come at the expense of reliability.

Branches

SDAB Accreditation

SDAB Head Office

SDAB Sanatan Dharma Accreditation Board
SDAB House
C/O Mr.Garry 54, Glengarnock Avenue,
E-14 3BP Isle Of Dogs, London UK
Tel .: +44-8369083940
email: info@sanatanboards.com
Website: www.sanatanboards.com

MUMBAI Head Office

Sanatan Dharma Accreditation Board (SDAB)
SDAB House
B-401, New Om Kaveri Chs. Ltd., Nagindas pada,
Next To Shiv Sena Office, Nallasopara (E)
Tel .: +91-7499991895
email: info@sanatanboards.com
Website: www.sanatanboards.com

DELHI-NCR Regd. Office

Sanatan Dharma Accreditation Board (SDAB)
SDAB House
Asaoti, Dist Palwal
Faridabad Delhi NCR, Haryana
Tel .: +91-7979801035
Fax: +91-250 2341170
Website: www.sanatanboards.com

sanatanboards